Table 5.
Stability of LVFX under different storage conditions (n = 5).
| Biosamples | Spiked concentration (ng/mL) | Calculated concentration (ng/mL) | ||
|---|---|---|---|---|
| Room temperature | Cold storage | Three freeze-thaw cycles | ||
| LVFX in liver tissue | 10.02 | 9.36 ± 0.44 | 9.28 ± 0.85 | 9.60 ± 0.94 |
| 100.20 | 102.33 ± 8.31 | 102.92 ± 10.23 | 108.10 ± 3.75 | |
| 5010.00 | 4887.83 ± 105.12 | 4738.62 ± 157.74 | 4798.11 ± 159.01 | |
|
| ||||
| LVFX in urine | 10.02 | 8.98 ± 0.97 | 9.22 ± 0.99 | 10.50 ± 0.75 |
| 200.40 | 207.47 ± 10.63 | 212.35 ± 11.46 | 197.20 ± 10.17 | |
| 4008.00 | 3869.70 ± 143.60 | 3888.71 ± 161.29 | 3833.85 ± 91.54 | |
|
| ||||
| LVFX in feces | 10.02 | 9.02 ± 0.84 | 9.74 ± 0.67 | 9.33 ± 0.82 |
| 20.04 | 20.96 ± 1.66 | 18.75 ± 1.19 | 21.44 ± 0.83 | |
| 200.40 | 192.05 ± 17.68 | 191.49 ± 18.34 | 196.81 ± 13.40 | |